ArticleInternational journal of general medicine2025
Impact of Intravenous Ferric Carboxymaltose on Quality of Life in Patients with Iron Deficiency Anemia: A Prospective Observational Study.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Iron deficiency anemia (IDA) is a major public health concern. Intravenous (IV) iron supplementation serves as an effective alternative when oral iron therapy fails or is not tolerated. This study aimed to evaluate the efficacy, safety, and impact on quality of life of ferric carboxymaltose in the treatment of IDA. Methods: In this prospective observational study conducted between June 2023 and February 2025, a total of 528 patients with IDA-unresponsive or intolerant to oral iron-received IV ferric carboxymaltose. Doses were calculated using the Ganzoni formula. Hematological parameters and quality of life were assessed pre- and 30 days post-treatment using laboratory tests and the WHOQOL-BREF questionnaire. Adverse events were recorded during a 30-day follow-up. Results: The mean age was 41.56 ± 12.33 years, with 92.4% female participants. Hemoglobin increased from 9.17 ± 1.36 to 13.12 ± 0.82 g/dL, and ferritin exhibited a substantial rise from 6.23 ± 4.38 to 178.91 ± 123.99 ng/mL (both p < 0.001). Mild side effects occurred in 11.36% of cases; no serious adverse events were observed. Significant improvements were recorded in physical and psychological domains of quality of life (p < 0.001). Hypophosphatemia was more frequent in patients receiving > 1750 mg of iron and with pre-treatment phosphorus levels < 3.05 mg/dL. Conclusion: IV ferric carboxymaltose is a safe and effective therapy for IDA, offering rapid hematological recovery and improved quality of life. However, hypophosphatemia remains a concern at higher doses, warranting close monitoring and further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.